

and
Prosperous New Year 2009
Be always at war with your vices, at peace with your neighbors, and let each New Year find you a better man
- Benjamin Franklin
Mesothelioma is a kind of a cancer which is generally caused if you have been a victim of asbestos. The mesothelial cells shape the cavity of the chest, abdominal and your heart. The outer surface of most of the internal organs is also covered by these cells. The cells also form a tissue called mesothelium.


Ohio State University scientists believe they are the first in the world to study the molecular underpinnings of cancer by probing individual bonds between an asbestos fiber and human cells.
Though any clinical application is years away, the researchers hope their findings could aid in drug development efforts targeting illnesses caused by excessive exposure to asbestos, including the deadly cancer called mesothelioma. The researchers use atomic force microscopy to observe how a single asbestos fiber binds with a specific receptor protein on cell surfaces. They suspect that at least one of the more lethal forms of asbestos triggers a cascade of events inside cells that eventually lead to illness, sometimes decades later.
The conditions most commonly associated with long-term exposure to airborne asbestos are lung cancer; asbestosis, a chronic respiratory disease; and mesothelioma, a cancer that forms in the membrane lining most internal organs of the body, including the lungs.
Read the full story @ http://www.news-medical.net/?id=44441Considering society and people's health, a safety action plan is initiated by the Minister for Australia's State Industrial Relations in order to prevent the mesothelioma and asbestos related diseases. This plan provides necessary guidance and training materials to the workers and tradesmen especially those who working in the industries like building companies, construction companies, etc.
Paul Caica, Minister of Industrial Relations, held the launch at a service during the Asbestos Victims Memorial Day. Mr. Caica stated the plan would incorporate five strategic initiatives focusing on many aspects of society:
Due to a large rate of asbestos use in mining, Australia has one of the highest rates of mesothelioma in the world. According to recent studies, over 600 cases are diagnosed each year in Australia and that number is not expected to decline. It is estimated that most public buildings, hospitals, schools and homes built between 1840 and 1987 in Australia contain asbestos. The Asbestos Action Plan demonstrates the Australian Government’s commitment to work together with industry and community organizations to address this terrible contagion.
For the most up-to-date information and news on mesothelioma, visit http://mesothelioma-law-now.com/ . Individuals can also visit http://www.LegalView.com to learn about other legal conditions ranging from the latest on Nephrogenic Systemic Fibrosis treatments to developing a Ketek lawsuit.
Mesothelioma is one of the deadliest diseases known to man. The average life span of an inflicted person from the time of diagnosis until death is less than 24 months. It�s a disease that strikes approximately 3,000 United States citizens each and every year. Hard working people who have labored for a lifetime to provide for their families, doing the work that keeps this country running and a great place to live. They worked in factories, at shipyards, in mines, for the US military, as engineers, as pipefitters, as steel workers, as auto mechanics, and in so many other professions. They came home to their loved ones exhausted and covered in dirt and dust, tired but content that they had a job and were providing for their family. What they didn�t know was that they were slowly killing themselves
MARF
The Mesothelioma Applied Research Foundation (MARF), the national nonprofit organization whose mission is to eradicate mesothelioma as a life-ending disease, announced that it has received a major private gift of $200,000 earmarked specifically for research into effective treatments for the disease.
The man who owns a home on Columbia Street that was referred to as "the cat house" by neighbors has filed a notice of claim for $1 million against the city of Watertown for razing its remains after a fire last year.
A notice of claim is a precursor to filing a lawsuit against a municipality.
Oliver J. Wisner is seeking compensation for the "arbitrary, capricious and malicious charging and billing for outrageous unnecessary work on the cleanup of ashes and debris" the claim states.
The Watertown lawyer owns the property at 1205-07 Columbia St., which burned down Nov. 12, forcing neighbors to evacuate their homes during the early morning hours. The heat from the blaze damaged nearby homes, one of which is still uninhabitable.
The city requested that Mr. Wisner remove the remaining debris from the duplex immediately following the blaze. In late December, the city hired Independent Commercial Contractors Inc., Lorraine, for $28,600 to clean the site and remove asbestos. Mr. Wisner was then billed for the job.
Mr. Wisner bought the home June 21, despite the previous owner not allowing him to completely inspect it beforehand, the notice states.
Once the purchase was complete, Mr. Wisner hired cleaners to clear debris from the home.
"The cleaners discovered more than 10 bodies of long-dead cats in the building," the notice states. "The odor from the house and the Dumpsters brought numerous complaints from neighbors."
In June, the city Code Enforcement Office found that an upstairs bathtub in 1205 Columbia St. was filled with cat feces, and cat skeletons were found throughout the apartment.The property was condemned and the tenant, Michael J. Sias, was removed.
Mr. Sias, 58, now of 536 Emerson St., Apt. 103, is facing an animal-cruelty charge on allegations that between June 25 and July 3 he deprived seven cats of necessary sustenance in his former home, "permitting unjustifiable physical pain, suffering and death," according to a city police document. He was charged Tuesday and faces prosecution in City Court.
Some live cats were taken from the home by the SPCA, others were euthanized and six frozen bodies that were found in an operating freezer were sent to Cornell University, Ithaca, for a forensics examination.
Mr. Wisner claims that "it was a matter of public knowledge that persons in the city of Watertown, New York, had called for the burning of the duplex." Throughout the notice, he maintains that an arsonist started the fire and that police did not properly follow leads.
The cause of the fire was never determined and police never made an arrest.
"My position is that there was no emergency and the demolition charges were unlawful and unreasonable and should be reviewed by a court and disallowed as an unlawful taking of private property," the notice states.
Mr. Wisner is asking for $100,000 for the loss of the house and $900,000 for "harassment causing great mental stress and depression." He plans to retain an attorney, the notice states.
City Attorney Robert J. Slye said he did not want to comment about the notice when contacted Friday afternoon.
"We'll certainly wait to see what Mr. Wisner has to say and if he files a suit," he said.
Times staff writer David C. Shampine contributed to this report.

Modern life is becoming faster and faster. Every day we have to solve different problems and meet many people just because you do not want to leg behind the pace of life or just earn money for a living.
Of course we like our job but one day your boss can give you the most difficult task which you will not be able to complete at once and as a result you can be so depressed to do anything at all. And of course, you will need depression help but it is not very easy. Some people start drinking a lot of alcohol or even use drugs. But it is not a way out because it can only make the situation worse. Only specialists can help because a depressed person already is in a situation where he does not see solutions of his problems. In this case guided meditation can become a useful tool because a specialist can teach a person to overcome all his problems himself. This effect is achieved with the help of meditation using special words and of course special music. This method is very effective and was used for a long time and proved to be very effective.
VICTIMS of York's asbestos timebomb have been given a major boost after a medicine rationing organisation ruled they are entitled to a vital drug.
The National Institute for Clinical Excellence (NICE) has decided the drug Alimta should be made available to patients with the asbestos-related cancer mesothelioma.
The York Asbestos Support Group today hailed the decision, saying that while the drug was not a cure, it could both extend life and alleviate symptoms for patients and was the only treatment available.
"The NICE decision brings to a conclusion an approval process which started almost three years ago and which led to one of the worst examples of the health postcode lottery," said the group's delighted founder Kim Daniells.
"Hundreds of patients across the UK were refused treatment with this drug whilst those in Scotland, the North West and North East of England could access treatment."
She said NICE had rejected an appeal against an original decision to approve the use of the drug for the treatment of the condition, which was a fatal tumour of the lung pleura caused by exposure to asbestos.
"In the last three years, many hundreds of patients have been diagnosed with the condition and gone on to die without ever being able to access the treatment. Hopefully this situation will now come to an end."
She said NICE's guidance meant primary care trusts would now be obliged to provide uniform treatment.
They would be given the option of a 90-day lead-in period following the official announcement, but she hoped the guidance would result in mesothelioma sufferers gaining prompt access to the treatment they needed and deserved.
The decision could benefit former York Carriageworks employees who fall victim in future to mesothelioma.
Staff were widely exposed to deadly asbestos dust fibres during the 1950s, 1960s and 1970s, and even in the 1980s after some measures had been brought in to provide protection to staff.
Scores of ex-workers have died from the devastating cancer.
A NICE spokesman said Alimta was being recommended as a possible treatment for malignant pleural mesothelioma in people with advanced disease, and whose cancer was not suitable for surgical removal and who met certain other conditions.
Alfacell Corp. licensed U.S. commercialization rights for the Phase III cancer drug Onconase (ranpirnase) to Strativa Pharmaceuticals in a deal worth up to $225 million.
Just $5 million will change hands up front, but both Alfacell and Strativa stand to gain much more if their gamble in choosing each other as partners pays off. Specifically, Alfacell could get $30 million for FDA approval of Onconase in unresectable malignant mesothelioma (UMM) and up to $190 million for milestones tied to Onconase sales as well as development and commercialization of the drug in additional indications. Alfacell also would receive double-digit royalties and retains a co-promotion option.
For Alfacell, the gamble lies in choosing Strativa, the recently-launched specialty pharmaceutical division of Par Pharmaceutical Cos. Inc. So far, Strativa markets just one product: Megace ES for anorexia, cachexia and unexplained weight loss in HIV patients. Although the company has deals in place for three additional late-stage products, all three are for HIV or cancer supportive care, and Onconase would be Strativa's first true oncology therapeutic.
Lawrence Kenyon, executive vice president and chief financial officer for Alfacell, told BioWorld Today that Onconase has been the subject of "bids from multiple companies for a number of years." Strativa was selected because it had the hunger of a start-up looking to build an oncology business focused on niche products, combined with the resources and infrastructure of Par Pharmaceuticals, he said.
For Strativa, the gamble lies in Onconase's somewhat checkered development history. The drug, a natural ribonuclease isolated from frog eggs, failed a Phase III trial in pancreatic cancer and its first Phase III trial in UMM.
In the pancreatic cancer trial, a preliminary analysis showed that Onconase plus tamoxifen failed to improve survival compared to 5-fluorouracil. Kenyon said part of the problem was an inability to recruit sufficiently healthy patients into the trial, and the pancreatic cancer program subsequently was discontinued. (See BioWorld Today, July 16, 1998.)
The first Phase III UMM trial compared Onconase as a monotherapy to doxorubicin. Again, there was no survival difference in the overall population, but Kenyon said a retrospective analysis showed that the sickest patients had been disproportionately weighted to the Onconase group. Backing them out of the analysis resulted in a two-month survival difference.
Onconase is now being studied in a Phase IIIb trial designed to confirm the positive data seen in the Phase III subset analysis. The trial, which was designed in coordination with the FDA, compares Onconase plus doxorubicin to doxorubicin alone in the less-severe groups of UMM patients. Enrollment of 428 patients is complete, and Kenyon said the company is "very close" to obtaining the number of clinical events needed to analyze the data.
Under the deal with Strativa, Alfacell will continue to fund development, manufacturing and regulatory work with Onconase, including the ongoing Phase IIIb trial. Strativa will fund U.S. commercialization.
Previous deals with US Pharmacia affiliate USP Pharma Spolka Z.O.O. and Genesis Pharma SA cover Onconase commercialization in Eastern Europe and certain Southeast European countries, respectively.
As of Oct. 31, Alfacell reported $5.4 million in cash and equivalents, most of which was earmarked to support the Onconase trial and new drug application filing. Once the filing is submitted, Alfacell intends to work with Strativa on additional indications for Onconase, including the possibility of moving a non-small-cell lung cancer program into Phase II.
Kenyon said the money from Strativa also will allow Alfacell to "ramp up" its preclinical work on AC 03-636 for glioma and antiviral indications, AC CJ-001 for glioma, and AC CJ-002 for non-Hodgkin's lymphoma.
The government says the chemotherapy agent Alimta - the only treatment available specifically for the killer cancer of the lung or stomach lining - will be listed on the Pharmaceutical Benefits Scheme (PBS) from today.
Health Minister Nicola Roxon said the listing of Alimta was an important announcement that followed the "tireless campaigning" of Bernie Banton, who died, aged 61, in November from the disease.
"Bernie was a great Australian hero and it is due to his efforts that many people will understand the significance of this decision," she said.
About 600 Australians are diagnosed annually with mesothelioma, but the long lag time between exposure to asbestos and the onset of symptoms means its prevalence is tipped to rise in the future.
Medical studies have estimated 18,000 people will have become victims of the disease by 2020.
Alimta, which can increase survival time and improve a sufferer's quality of life, has been out of reach for many patients at $20,000 or more for six treatments.
From today, sufferers will pay a maximum of $31.30 for each prescription. Eligible concession-patients will pay $5 for each prescription.
The subsidy will cost the government about $26 million annually and is expected to benefit about 300 people a year.
The listing of the drug became an election issue after Mr Banton criticised then health minister Tony Abbott for failing to personally receive a 17,000-signature petition brought to his Sydney electoral office in October.
Mr Abbott was forced into an embarrassing apology after questioning whether the dying campaigner's motives for speaking out were "pure of heart".
A week later, a government-appointed board recommended the drug be added to the PBS after three times rejecting its listing since 2004.
Mr Abbott bypassed the normal process of cabinet approval by immediately announcing the drug's listing.
Until now, only about half of Australians suffering mesothelioma were getting easy access to the palliative care drug through state government subsidy and workplace compensation schemes.
A Maryborough cancer sufferer has welcomed the placing of a chemotherapy drug onto the Pharmaceutical Benefits Scheme (PBS) this week.
In 1995, 65-year-old Gary Morse was diagnosed with an incurable lung cancer.
He says the chemotherapy and asbestos cancer drug, Alimta, helped him greatly last year.
But he say it would have cost him about $20,000 if his oncologist had not persuaded a private health insurer to pay the cost.
"We have private insurance and he [the oncologist] got in contact with them and got them to agree to pay for the first three treatments and the results were great," he said.
"Then he talked them into paying for the next one and of course now it's come onto the free list, which is better still.
"If we hadn't had private insurance we would have had to take it out of our superannuation retirement fund.
"I know of another one person who's on it, and it's increased his life span, and of course it's also going to increase mine too.
"This year 22 of our family were all together for Christmas, the first time ever, and I thought it was going to be the 'last supper', actually, until this new drug come on the scene.
"Now we can look forward to the future. I'm really pleased with it."